American Century Companies Inc. Boosts Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• American Century Companies Inc. increased its holdings in NewAmsterdam Pharma by 52.6%, owning 528,830 shares worth approximately $10.83 million at the end of the first quarter.
• Wall Street analysts are optimistic about NewAmsterdam Pharma, with several firms, including Wells Fargo and Royal Bank of Canada, issuing "buy" ratings and setting prices targets around $39 to $45.
• The company's stock recently surged by 2.0%, trading at $25.19, after reporting better-than-expected earnings per share of ($0.15) compared to the consensus estimate of ($0.52).

American Century Companies Inc. grew its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 52.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 528,830 shares of the company's stock after purchasing an additional 182,258 shares during the quarter. American Century Companies Inc. owned about 0.48% of NewAmsterdam Pharma worth $10,825,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NAMS. Deerfield Management Company L.P. Series C raised its stake in NewAmsterdam Pharma by 378.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock worth $110,879,000 after buying an additional 3,412,590 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 23.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after acquiring an additional 3,061,224 shares during the last quarter. Wellington Management Group LLP grew its holdings in NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after acquiring an additional 2,222,900 shares during the period. Woodline Partners LP raised its position in shares of NewAmsterdam Pharma by 108.7% in the 4th quarter. Woodline Partners LP now owns 2,430,782 shares of the company's stock worth $62,471,000 after acquiring an additional 1,266,105 shares in the last quarter. Finally, RA Capital Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 9.7% in the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company's stock valued at $227,316,000 after purchasing an additional 781,000 shares during the period. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Up 0.4%

NAMS traded up $0.10 during trading on Monday, hitting $24.05. 850,991 shares of the company's stock were exchanged, compared to its average volume of 826,589. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The stock has a market cap of $2.71 billion, a P/E ratio of -14.85 and a beta of -0.01. The business's 50 day moving average is $22.41 and its two-hundred day moving average is $20.41.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

NAMS has been the subject of several recent analyst reports. Royal Bank Of Canada raised their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price target for the company. Finally, Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.55.

Insider Buying and Selling

In related news, COO Douglas F. Kling sold 100,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer owned 44,000 shares of the company's stock, valued at $848,760. The trade was a 69.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares of the company's stock, valued at $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 12,835 shares of company stock worth $248,134 and have sold 256,881 shares worth $5,445,954. 20.84% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.